How would you decide whether a quality problem requires an FDA Field Alert Report?

Why

21 CFR 314.81(b)(1) is an early warning system. The trigger is information about distributed product, not a finished investigation. FDA's 2021 guidance answers the common interpretation questions.

An OOS result on undistributed product does not need a report, but an OOS result on a distributed batch does unless it is scientifically invalidated, such as a confirmed lab error, within the 3 working days. Complaints should be evaluated within 3 working days to decide if they meet the criteria. A component found to fail specification after use in a distributed batch triggers a report unless you show within 3 working days that it does not affect that batch.

A media fill failure calls for an assessment of distributed product, and a report if that assessment finds qualifying information. Identifying and correcting the root cause within 3 working days does not remove the requirement, the report simply includes what was found. Products distributed only abroad under the NDA are still covered.

The guidance recommends follow-up and final reports to update FDA as the investigation develops. Biologics licensed under a BLA follow a different route, biological product deviation reports under 21 CFR 600.14, due within 45 calendar days. Because the clock is short, a site needs a procedure that routes potential FAR information to the right person on day one.